# Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients

> **NCT01276457** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 223 (actual)

## Conditions studied

- Transplantation Infection

## Interventions

- **DRUG:** Everolimus 0.25 and 0.75 mg tablets
- **DRUG:** Cyclosporine very low dose (150-300 ng/mL) microemulsion
- **DRUG:** Cyclosporine low dose (350-500 ng/mL) microemulsion

## Key facts

- **NCT ID:** NCT01276457
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2011-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276457, "Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01276457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*